TWI878810B - 製造及使用因多昔芬(endoxifen)之方法 - Google Patents

製造及使用因多昔芬(endoxifen)之方法 Download PDF

Info

Publication number
TWI878810B
TWI878810B TW112107353A TW112107353A TWI878810B TW I878810 B TWI878810 B TW I878810B TW 112107353 A TW112107353 A TW 112107353A TW 112107353 A TW112107353 A TW 112107353A TW I878810 B TWI878810 B TW I878810B
Authority
TW
Taiwan
Prior art keywords
endoxifen
oral formulation
enteric
enteric oral
formula
Prior art date
Application number
TW112107353A
Other languages
English (en)
Chinese (zh)
Other versions
TW202428251A (zh
Inventor
史提芬 Ｃ 貴
孫耀臨
王龍虎
吳昌容
黃全德
Original Assignee
美商阿托薩醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65635248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI878810(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商阿托薩醫療公司 filed Critical 美商阿托薩醫療公司
Publication of TW202428251A publication Critical patent/TW202428251A/zh
Application granted granted Critical
Publication of TWI878810B publication Critical patent/TWI878810B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)
  • Paper (AREA)
  • Dental Preparations (AREA)
  • Primary Cells (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW112107353A 2017-09-11 2018-09-10 製造及使用因多昔芬(endoxifen)之方法 TWI878810B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762556884P 2017-09-11 2017-09-11
US201762556799P 2017-09-11 2017-09-11
US62/556,799 2017-09-11
US62/556,884 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US62/624,787 2018-01-31
US201862693885P 2018-07-03 2018-07-03
US62/693,885 2018-07-03

Publications (2)

Publication Number Publication Date
TW202428251A TW202428251A (zh) 2024-07-16
TWI878810B true TWI878810B (zh) 2025-04-01

Family

ID=65635248

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112107353A TWI878810B (zh) 2017-09-11 2018-09-10 製造及使用因多昔芬(endoxifen)之方法
TW107131790A TWI793165B (zh) 2017-09-11 2018-09-10 製造及使用因多昔芬(endoxifen)之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107131790A TWI793165B (zh) 2017-09-11 2018-09-10 製造及使用因多昔芬(endoxifen)之方法

Country Status (12)

Country Link
US (8) US11261151B2 (enExample)
EP (1) EP3681491A4 (enExample)
JP (3) JP7766316B2 (enExample)
KR (2) KR20200052349A (enExample)
CN (2) CN111328280A (enExample)
AU (3) AU2018329202B2 (enExample)
CA (1) CA3073836A1 (enExample)
IL (3) IL319158A (enExample)
MX (1) MX2020002649A (enExample)
SG (1) SG11202002105WA (enExample)
TW (2) TWI878810B (enExample)
WO (1) WO2019051416A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
US12201591B2 (en) * 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110564962B (zh) * 2019-10-14 2020-12-22 中南大学 一种黑白钨混合矿的冶炼方法
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用
CA3241735A1 (en) * 2022-01-12 2023-07-20 Yao-Lin Sun Compositions of (z)-endoxifen and methods of enrichment thereof
IL316562A (en) * 2022-04-26 2024-12-01 Atossa Therapeutics Inc High-dose and convenient formulations of endoxifen
WO2025019775A1 (en) * 2023-07-19 2025-01-23 Atossa Therapeutics, Inc. Endoxifen compositions and methods of use thereof and synthesis thereof
WO2025137145A1 (en) 2023-12-18 2025-06-26 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof
WO2025151443A1 (en) 2024-01-08 2025-07-17 Atossa Therapeutics, Inc. Endoxifen for treatment of rare cancers
WO2025207636A1 (en) 2024-03-25 2025-10-02 Atossa Therapeutics, Inc. Endoxifen for treating duchenne muscular dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
EP0168175B1 (en) 1984-06-12 1987-11-19 National Research Development Corporation Preparation of tamoxifen
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
AU5409699A (en) 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
DK1443917T3 (da) 2001-11-07 2006-07-17 Synthon Bv Tamsulosintabletter
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
WO2004087123A1 (en) 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE324880T1 (de) 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
NZ544851A (en) 2003-06-23 2008-03-28 Macrochem Corp A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005070951A1 (en) 2004-01-16 2005-08-04 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1865992A2 (en) 2005-03-31 2007-12-19 Mytogen Inc. Treatment for heart disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
EP1871750A1 (en) 2005-07-06 2008-01-02 Sicor, Inc. Improved process for the preparation of letrozole
CA2617934A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
RU2008118363A (ru) 2005-10-12 2009-11-20 Кова Ко., Лтд. (Jp) Ионтофоретический препарат для лечения рака молочной железы и/или мастита
US20090208944A1 (en) 2005-12-09 2009-08-20 Goetz Matthew P Assessing outcomes for breast cancer patients treated with tamoxifen
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
EP2029557A1 (en) 2006-06-05 2009-03-04 Cadila Healthcare Ltd. A process for preparing pure anastrozole
AR063120A1 (es) 2006-10-05 2008-12-30 Panacea Biotec Ltd Composiciones inyectables de deposito y proceso para prepararlas
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US20080207644A1 (en) 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2823407C (en) 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2009032699A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
US8198460B2 (en) 2007-11-28 2012-06-12 Fresenius Kabi Oncology Ltd. Process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009129352A2 (en) 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2350111A1 (en) 2008-10-15 2011-08-03 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
EP3202420B1 (en) 2008-12-11 2020-03-04 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
CN101891635B (zh) * 2009-05-21 2014-06-04 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011031561A2 (en) 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9200045B2 (en) 2011-03-11 2015-12-01 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US20120301541A1 (en) 2011-05-24 2012-11-29 Haronsky Elina Compressed core for pharmaceutical composition
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
EP3296300B1 (en) 2012-03-05 2019-08-07 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
WO2014012117A1 (en) 2012-07-13 2014-01-16 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
EP2909163A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
KR20210108497A (ko) 2013-02-26 2021-09-02 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
WO2014141292A2 (en) 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
TW201536278A (zh) * 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
EP3057985A4 (en) 2013-10-18 2017-05-31 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20160375234A1 (en) 2014-01-10 2016-12-29 Atossa Genetic Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CN106068121A (zh) 2014-03-11 2016-11-02 利普生物药剂公司 使用单一溶剂进行克罗米芬合成
WO2015187727A2 (en) 2014-06-04 2015-12-10 Atossa Genetics Inc. Molecular mammography
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团（天津）股份有限公司 托瑞米芬的合成方法
US20180049999A1 (en) 2015-04-14 2018-02-22 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
US10314854B2 (en) 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
WO2017011623A1 (en) 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
AU2018330314A1 (en) 2017-09-11 2020-03-19 Atossa Therapeutics, Inc. Topical compositions
TW201919594A (zh) 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity

Also Published As

Publication number Publication date
IL272924B2 (en) 2024-01-01
IL272924B1 (en) 2023-09-01
AU2023200013B2 (en) 2024-09-12
MX2020002649A (es) 2020-09-25
JP2025061858A (ja) 2025-04-11
IL319158A (en) 2025-04-01
US12281056B2 (en) 2025-04-22
JP7766316B2 (ja) 2025-11-10
US20250282710A1 (en) 2025-09-11
AU2018329202A1 (en) 2020-03-19
WO2019051416A1 (en) 2019-03-14
US11680036B1 (en) 2023-06-20
US12479790B2 (en) 2025-11-25
US11572334B2 (en) 2023-02-07
IL304863A (en) 2023-10-01
KR20240155974A (ko) 2024-10-29
US20240425443A1 (en) 2024-12-26
US20220242816A1 (en) 2022-08-04
US11261151B2 (en) 2022-03-01
TW201919596A (zh) 2019-06-01
IL304863B1 (en) 2025-04-01
IL272924A (en) 2020-04-30
CA3073836A1 (en) 2019-03-14
US12275684B2 (en) 2025-04-15
AU2024278243A1 (en) 2025-01-02
EP3681491A4 (en) 2021-06-30
TWI793165B (zh) 2023-02-21
AU2023200013A1 (en) 2023-02-09
US12071391B2 (en) 2024-08-27
US20200207704A1 (en) 2020-07-02
AU2018329202B2 (en) 2022-10-27
EP3681491A1 (en) 2020-07-22
JP2023126540A (ja) 2023-09-07
JP2020533283A (ja) 2020-11-19
TW202428251A (zh) 2024-07-16
CN111328280A (zh) 2020-06-23
US20230365490A1 (en) 2023-11-16
CN116832020A (zh) 2023-10-03
IL304863B2 (en) 2025-08-01
KR20200052349A (ko) 2020-05-14
US20250223256A1 (en) 2025-07-10
SG11202002105WA (en) 2020-04-29
US20240327333A1 (en) 2024-10-03
US20230183166A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
TWI878810B (zh) 製造及使用因多昔芬(endoxifen)之方法
JP2023126540A5 (enExample)
TW202340135A (zh) （ｚ）—因多昔芬之組合物及其富集方法
KR20240093500A (ko) 암 치료를 위한 엔독시펜
HK40031003A (en) Methods for making and using endoxifen
TW202510843A (zh) 因多昔芬（ｅｎｄｏｘｉｆｅｎ）組合物及其使用方法及其合成
CN118647598A (zh) (z)-因多昔芬的组合物和其富集方法